Computational medicinal chemistry in fragment-based drug discovery: what, how and when.

The use of fragment-based drug discovery (FBDD) has increased in the last decade due to the encouraging results obtained to date. In this scenario, computational approaches, together with experimental information, play an important role to guide and speed up the process. By default, FBDD is generally considered as a constructive approach. However, such additive behavior is not always present, therefore, simple fragment maturation will not always deliver the expected results. In this review, computational approaches utilized in FBDD are reported together with real case studies, where applicability domains are exemplified, in order to analyze them, and then, maximize their performance and reliability. Thus, a proper use of these computational tools can minimize misleading conclusions, keeping the credit on FBDD strategy, as well as achieve higher impact in the drug-discovery process. FBDD goes one step beyond a simple constructive approach. A broad set of computational tools: docking, R group quantitative structure-activity relationship, fragmentation tools, fragments management tools, patents analysis and fragment-hopping, for example, can be utilized in FBDD, providing a clear positive impact if they are utilized in the proper scenario - what, how and when. An initial assessment of additive/non-additive behavior is a critical point to define the most convenient approach for fragments elaboration.

[1]  O. Rabal,et al.  Discovery of mitogen-activated protein kinase-interacting kinase 1 inhibitors by a comprehensive fragment-oriented virtual screening approach. , 2010, Journal of medicinal chemistry.

[2]  Robert Kiss,et al.  Virtual Fragment Docking by Glide: a Validation Study on 190 Protein-Fragment Complexes , 2010, J. Chem. Inf. Model..

[3]  Gerhard Klebe,et al.  Non-additivity of functional group contributions in protein-ligand binding: a comprehensive study by crystallography and isothermal titration calorimetry. , 2010, Journal of molecular biology.

[4]  Roman A Laskowski,et al.  Chemical fragments that hydrogen bond to Asp, Glu, Arg, and His side chains in protein binding sites. , 2010, Journal of medicinal chemistry.

[5]  A. Cavalli,et al.  Molecular basis of cyclooxygenase enzymes (COXs) selective inhibition , 2010, Proceedings of the National Academy of Sciences.

[6]  Tingjun Hou,et al.  Drug and Drug Candidate Building Block Analysis , 2010, J. Chem. Inf. Model..

[7]  Aurélien Grosdidier,et al.  Rational design of indoleamine 2,3-dioxygenase inhibitors. , 2010, Journal of medicinal chemistry.

[8]  Julen Oyarzabal,et al.  Optimizing the Performance of In Silico ADMET General Models According to Local Requirements: MARS Approach. Solubility Estimations As Case Study , 2009, J. Chem. Inf. Model..

[9]  M. Clark,et al.  Fragment-Based Prediction of the Clinical Occurrence of Long QT Syndrome and Torsade de Pointes , 2009, J. Chem. Inf. Model..

[10]  Y. Shaul,et al.  The nanny model for IDPs. , 2009, Nature chemical biology.

[11]  L. Kay,et al.  NMR spectroscopy brings invisible protein states into focus. , 2009, Nature chemical biology.

[12]  R. Nussinov,et al.  The role of dynamic conformational ensembles in biomolecular recognition. , 2009, Nature chemical biology.

[13]  Ian A. Watson,et al.  Kinase inhibitor data modeling and de novo inhibitor design with fragment approaches. , 2009, Journal of medicinal chemistry.

[14]  Anna Vulpetti,et al.  Design and NMR-based screening of LEF, a library of chemical fragments with different local environment of fluorine. , 2009, Journal of the American Chemical Society.

[15]  Amedeo Caflisch,et al.  Discovery of Plasmepsin Inhibitors by Fragment‐Based Docking and Consensus Scoring , 2009, ChemMedChem.

[16]  J. Bajorath,et al.  Methods for Computer‐Aided Chemical Biology. Part 5: Rationalizing the Selectivity of Cathepsin Inhibitors on the Basis of Molecular Fragments and Topological Feature Distributions , 2009, Chemical biology & drug design.

[17]  Paolo Carnevali,et al.  Fragment-Based Computation of Binding Free Energies by Systematic Sampling , 2009, J. Chem. Inf. Model..

[18]  Eugen Lounkine,et al.  Fragment Formal Concept Analysis Accurately Classifies Compounds with Closely Related Biological Activities , 2009, ChemMedChem.

[19]  Kuo-Chen Chou,et al.  Investigation into adamantane-based M2 inhibitors with FB-QSAR. , 2009, Medicinal chemistry (Shariqah (United Arab Emirates)).

[20]  Gerhard Müller,et al.  Fragment-based lead generation: identification of seed fragments by a highly efficient fragment screening technology , 2009, J. Comput. Aided Mol. Des..

[21]  Mark Whittaker,et al.  The multiple roles of computational chemistry in fragment-based drug design , 2009, J. Comput. Aided Mol. Des..

[22]  Ian H. Gilbert,et al.  One Scaffold, Three Binding Modes: Novel and Selective Pteridine Reductase 1 Inhibitors Derived from Fragment Hits Discovered by Virtual Screening , 2009, Journal of medicinal chemistry.

[23]  Lorenz C. Blum,et al.  970 million druglike small molecules for virtual screening in the chemical universe database GDB-13. , 2009, Journal of the American Chemical Society.

[24]  Hongming Wang,et al.  Virtual fragment screening: an exploration of various docking and scoring protocols for fragments using Glide , 2009, J. Comput. Aided Mol. Des..

[25]  Roderick E. Hubbard,et al.  Lessons for fragment library design: analysis of output from multiple screening campaigns , 2009, J. Comput. Aided Mol. Des..

[26]  Matthew Paul Gleeson,et al.  QM/MM As a Tool in Fragment Based Drug Discovery. A Cross-Docking, Rescoring Study of Kinase Inhibitors , 2009, J. Chem. Inf. Model..

[27]  Stefan Senger,et al.  Using Tversky Similarity Searches for Core Hopping: Finding the Needles in the Haystack , 2009, J. Chem. Inf. Model..

[28]  Michael Devereux,et al.  Quantum Isostere Database: A Web-Based Tool Using Quantum Chemical Topology To Predict Bioisosteric Replacements for Drug Design , 2009, J. Chem. Inf. Model..

[29]  Woody Sherman,et al.  Energetic analysis of fragment docking and application to structure-based pharmacophore hypothesis generation , 2009, J. Comput. Aided Mol. Des..

[30]  M. Pellecchia Fragment-based drug discovery takes a virtual turn. , 2009, Nature chemical biology.

[31]  Somesh D. Sharma,et al.  Managing protein flexibility in docking and its applications. , 2009, Drug discovery today.

[32]  Daniel P. Vercauteren,et al.  Fragment-based prediction of cytochromes P450 2D6 and 1A2 inhibition by recursive partitioning , 2009, SAR and QSAR in environmental research.

[33]  Susumu Goto,et al.  Extraction and Analysis of Chemical Modification Patterns in Drug Development , 2009, J. Chem. Inf. Model..

[34]  B. Shoichet,et al.  Molecular docking and ligand specificity in fragment-based inhibitor discovery. , 2009, Nature chemical biology.

[35]  Julen Oyarzabal,et al.  Novel approach for chemotype hopping based on annotated databases of chemically feasible fragments and a prospective case study: new melanin concentrating hormone antagonists. , 2009, Journal of medicinal chemistry.

[36]  Niklas Blomberg,et al.  Design of compound libraries for fragment screening , 2009, J. Comput. Aided Mol. Des..

[37]  Ismael Zamora,et al.  SHOP: Receptor-Based Scaffold HOPping by GRID-Based Similarity Searches , 2009, J. Chem. Inf. Model..

[38]  A. Andricopulo,et al.  Fragment-Based QSAR and Molecular Modeling Studies on a Series of Discodermolide Analogs as Microtubule-Stabilizing Anticancer Agents , 2009 .

[39]  Hanna Geppert,et al.  Methods for Computer‐Aided Chemical Biology. Part 4: Selectivity Searching for Ion Channel Ligands and Mapping of Molecular Fragments as Selectivity Markers , 2009, Chemical biology & drug design.

[40]  Dima Kozakov,et al.  Fragment-based identification of druggable 'hot spots' of proteins using Fourier domain correlation techniques , 2009, Bioinform..

[41]  T. Poulos,et al.  Discovery of highly potent and selective inhibitors of neuronal nitric oxide synthase by fragment hopping. , 2009, Journal of medicinal chemistry.

[42]  Adriaan P. IJzerman,et al.  Substructure Mining of GPCR Ligands Reveals Activity-Class Specific Functional Groups in an Unbiased Manner , 2009, J. Chem. Inf. Model..

[43]  Adriano D. Andricopulo,et al.  Fragment-based QSAR: perspectives in drug design , 2009, Molecular Diversity.

[44]  K. Chou,et al.  Fragment‐based quantitative structure–activity relationship (FB‐QSAR) for fragment‐based drug design , 2009, J. Comput. Chem..

[45]  Paul Labute,et al.  Detection and assignment of common scaffolds in project databases of lead molecules. , 2009, Journal of medicinal chemistry.

[46]  Holger Claussen,et al.  Searching Fragment Spaces with Feature Trees , 2009, J. Chem. Inf. Model..

[47]  Bainan Wu,et al.  Fragment-based design of small molecule X-linked inhibitor of apoptosis protein inhibitors. , 2008, Journal of medicinal chemistry.

[48]  Philip Prathipati,et al.  Global Bayesian Models for the Prioritization of Antitubercular Agents , 2008, J. Chem. Inf. Model..

[49]  Peter Willett,et al.  Assessment of additive/nonadditive effects in structure-activity relationships: implications for iterative drug design. , 2008, Journal of medicinal chemistry.

[50]  Luca Sartori,et al.  Identification and Selection of "Privileged Fragments" Suitable for Primary Screening , 2008, J. Chem. Inf. Model..

[51]  Brian B. Masek,et al.  Virtual Screening for R-Groups, including Predicted pIC50 Contributions, within Large Structural Databases, Using Topomer CoMFA , 2008, J. Chem. Inf. Model..

[52]  Matthias Rarey,et al.  On the Art of Compiling and Using 'Drug‐Like' Chemical Fragment Spaces , 2008, ChemMedChem.

[53]  Wayne Vaccaro,et al.  Multiple and single binding modes of fragment-like kinase inhibitors revealed by molecular modeling, residue type-selective protonation, and nuclear overhauser effects. , 2008, Journal of medicinal chemistry.

[54]  Claudio N. Cavasotto and Narender Singh Docking and High Throughput Docking: Successes and the Challenge of Protein Flexibility , 2008 .

[55]  Hualin Xi,et al.  Predicting Kinase Selectivity Profiles Using Free-Wilson QSAR Analysis , 2008, J. Chem. Inf. Model..

[56]  Arup K. Ghose,et al.  Knowledge based prediction of ligand binding modes and rational inhibitor design for kinase drug discovery. , 2008, Journal of medicinal chemistry.

[57]  Eugen Lounkine,et al.  Formal concept analysis for the identification of molecular fragment combinations specific for active and highly potent compounds. , 2008, Journal of medicinal chemistry.

[58]  Paul G Wyatt,et al.  Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design. , 2008, Journal of medicinal chemistry.

[59]  K. Tam,et al.  High throughput solubility determination with application to selection of compounds for fragment screening. , 2008, Bioorganic & medicinal chemistry.

[60]  M. Congreve,et al.  Recent developments in fragment-based drug discovery. , 2008, Journal of medicinal chemistry.

[61]  Ian A. Watson,et al.  Chemical fragments as foundations for understanding target space and activity prediction. , 2008, Journal of medicinal chemistry.

[62]  Christian Lemmen,et al.  Similarity searching and scaffold hopping in synthetically accessible combinatorial chemistry spaces. , 2008, Journal of medicinal chemistry.

[63]  Maulik R. Patel,et al.  CoMFA and HQSAR studies on 6,7-dimethoxy-4-pyrrolidylquinazoline derivatives as phosphodiesterase10A inhibitors. , 2008, Bioorganic & medicinal chemistry.

[64]  T. Poulos,et al.  Minimal pharmacophoric elements and fragment hopping, an approach directed at molecular diversity and isozyme selectivity. Design of selective neuronal nitric oxide synthase inhibitors. , 2008, Journal of the American Chemical Society.

[65]  Karl Edman,et al.  Novel prostaglandin D synthase inhibitors generated by fragment-based drug design. , 2008, Journal of medicinal chemistry.

[66]  M. Murcko,et al.  Kinase-likeness and kinase-privileged fragments: toward virtual polypharmacology. , 2008, Journal of medicinal chemistry.

[67]  Hiroaki Wakabayashi,et al.  Predicting Key Example Compounds in Competitors' Patent Applications Using Structural Information Alone , 2008, J. Chem. Inf. Model..

[68]  Scott Boyer,et al.  Generation of in-silico cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A4 inhibition QSAR models , 2007, J. Comput. Aided Mol. Des..

[69]  Michel Petitjean,et al.  MolDiA: A Novel Molecular Diversity Analysis Tool, 1. Principles and Architecture , 2007, J. Chem. Inf. Model..

[70]  Glyn Williams,et al.  Fragment-based screening using X-ray crystallography and NMR spectroscopy. , 2007, Current opinion in chemical biology.

[71]  Jianfeng Pei,et al.  A Large Descriptor Set and a Probabilistic Kernel-Based Classifier Significantly Improve Druglikeness Classification , 2007, J. Chem. Inf. Model..

[72]  Roderick E Hubbard,et al.  The SeeDs approach: integrating fragments into drug discovery. , 2007, Current topics in medicinal chemistry.

[73]  Alexander A Alex,et al.  Fragment-based drug discovery: what has it achieved so far? , 2007, Current topics in medicinal chemistry.

[74]  N. Blomberg,et al.  An integrated approach to fragment-based lead generation: philosophy, strategy and case studies from AstraZeneca's drug discovery programmes. , 2007, Current topics in medicinal chemistry.

[75]  Jean M. Severin,et al.  Discovery and Design of Novel HSP90 Inhibitors Using Multiple Fragment‐based Design Strategies , 2007, Chemical biology & drug design.

[76]  V. Helms,et al.  Transient pockets on protein surfaces involved in protein-protein interaction. , 2007, Journal of medicinal chemistry.

[77]  Jonas Boström,et al.  Scaffold hopping, synthesis and structure-activity relationships of 5,6-diaryl-pyrazine-2-amide derivatives: a novel series of CB1 receptor antagonists. , 2007, Bioorganic & medicinal chemistry.

[78]  Gergely M Makara,et al.  On sampling of fragment space. , 2007, Journal of medicinal chemistry.

[79]  Anna Linusson,et al.  SHOP: scaffold HOPping by GRID-based similarity searches. , 2007, Journal of medicinal chemistry.

[80]  J. Kuneš,et al.  The Oriented Development of Antituberculotics (Part II): Halogenated 3‐(4‐Alkylphenyl)‐1,3‐benzoxazine‐2,4‐(3H)‐diones , 2007, Archiv der Pharmazie.

[81]  P. Vasanthanathan,et al.  QSAR study on pyridinone derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitor: a mixed approach. , 2007, Medicinal chemistry (Shariqah (United Arab Emirates)).

[82]  Marcel L Verdonk,et al.  Identification of inhibitors of protein kinase B using fragment-based lead discovery. , 2007, Journal of medicinal chemistry.

[83]  P. Hajduk,et al.  A decade of fragment-based drug design: strategic advances and lessons learned , 2007, Nature Reviews Drug Discovery.

[84]  K. Wanner,et al.  Methods and Principles in Medicinal Chemistry , 2007 .

[85]  Harald Mauser,et al.  Chemical Fragment Spaces for de novo Design , 2007, J. Chem. Inf. Model..

[86]  Santosh A. Khedkar,et al.  Encoding Type and Position in Peptide QSAR: Application to Peptides Binding to Class I MHC Molecule HLA-A*0201 , 2007 .

[87]  Robert J. Jilek,et al.  AllChem: generating and searching 1020 synthetically accessible structures , 2007, J. Comput. Aided Mol. Des..

[88]  R. J. Doerksen,et al.  Probing the physicochemical and structural requirements for glycogen synthase kinase-3alpha inhibition: 2D-QSAR for 3-anilino-4-phenylmaleimides. , 2006, Bioorganic & medicinal chemistry.

[89]  Petra Schneider,et al.  Scaffold-Hopping: How Far Can You Jump , 2006 .

[90]  P. Hajduk,et al.  Puzzling through fragment-based drug design , 2006, Nature chemical biology.

[91]  W. Jencks,et al.  Binding energy, specificity, and enzymic catalysis: the circe effect. , 2006, Advances in enzymology and related areas of molecular biology.

[92]  A. Caflisch,et al.  Automatic and efficient decomposition of two-dimensional structures of small molecules for fragment-based high-throughput docking. , 2006, Journal of medicinal chemistry.

[93]  Kerim Babaoglu,et al.  Deconstructing fragment-based inhibitor discovery , 2006, Nature chemical biology.

[94]  Stefan Schmitt,et al.  Do structurally similar ligands bind in a similar fashion? , 2006, Journal of medicinal chemistry.

[95]  C. E. Peishoff,et al.  A critical assessment of docking programs and scoring functions. , 2006, Journal of medicinal chemistry.

[96]  Matthew P. Repasky,et al.  Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. , 2006, Journal of medicinal chemistry.

[97]  Christopher W. Murray,et al.  Entropic Consequences of Linking Ligands , 2006 .

[98]  Harren Jhoti,et al.  Pyramid: An Integrated Platform for Fragment‐based Drug Discovery , 2006 .

[99]  P. Hajduk,et al.  SAR by NMR: An Analysis of Potency Gains Realized Through Fragment‐linking and Fragment‐elaboration Strategies for Lead Generation , 2006 .

[100]  Andrew R Leach,et al.  Fragment screening: an introduction. , 2006, Molecular bioSystems.

[101]  Mark Whittaker,et al.  Fragment screening by biochemical assay , 2006, Expert opinion on drug discovery.

[102]  Jürgen Bajorath,et al.  Assessment of Molecular Similarity from the Analysis of Randomly Generated Structural Fragment Populations , 2006, J. Chem. Inf. Model..

[103]  M. Pawłowski,et al.  Arylpiperazines with N-acylated amino acids as 5-HT1A receptor ligands. , 2006, Bioorganic & medicinal chemistry letters.

[104]  D. V. Von Hoff,et al.  Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approach , 2006, Molecular Cancer Therapeutics.

[105]  S. G. Kaskhedikar,et al.  Exploring Structural Requirements for Aldose‐Reductase Inhibition by 2,4‐Dioxo‐5‐(naphth‐2‐ylmethylene)‐3‐thiazolidinyl Acetic Acids and 2‐Thioxo Analogues: Fujita‐Ban and Hansch Approach , 2006, Archiv der Pharmazie.

[106]  Sandor Vajda,et al.  Characterization of protein-ligand interaction sites using experimental and computational methods. , 2006, Current opinion in drug discovery & development.

[107]  J. Chmielewski,et al.  Rapid synthesis and in situ screening of potent HIV-1 protease dimerization inhibitors. , 2006, Chemistry & biology.

[108]  A. Caflisch,et al.  In Silico Discovery of β-Secretase Inhibitors , 2006 .

[109]  Meir Glick,et al.  Prediction of Biological Targets for Compounds Using Multiple-Category Bayesian Models Trained on Chemogenomics Databases , 2006, J. Chem. Inf. Model..

[110]  Paul J Edwards,et al.  The reversed binding of beta-phenethylamine inhibitors of DPP-IV: X-ray structures and properties of novel fragment and elaborated inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[111]  Anthony Williams,et al.  Generation and Selection of Novel Estrogen Receptor Ligands Using the De Novo Structure-Based Design Tool, SkelGen , 2006, J. Chem. Inf. Model..

[112]  Christian Rummey,et al.  In silico fragment-based discovery of DPP-IV S1 pocket binders. , 2006, Bioorganic & medicinal chemistry letters.

[113]  Michael Wiese,et al.  Structure-activity relationships of a series of tariquidar analogs as multidrug resistance modulators. , 2006, Bioorganic & medicinal chemistry.

[114]  Dora M Schnur,et al.  Are target-family-privileged substructures truly privileged? , 2006, Journal of medicinal chemistry.

[115]  Qiang Zhang,et al.  Scaffold hopping through virtual screening using 2D and 3D similarity descriptors: ranking, voting, and consensus scoring. , 2006, Journal of medicinal chemistry.

[116]  Thomas Bäck,et al.  Mining a Chemical Database for Fragment Co-occurrence: Discovery of "Chemical Clichés" , 2006, J. Chem. Inf. Model..

[117]  P. Hajduk,et al.  Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis. , 2006, Journal of medicinal chemistry.

[118]  Gianni Chessari,et al.  Application of fragment screening and fragment linking to the discovery of novel thrombin inhibitors. , 2006, Journal of medicinal chemistry.

[119]  R. Morphy,et al.  Designed multiple ligands. An emerging drug discovery paradigm. , 2005, Journal of medicinal chemistry.

[120]  Edward R Zartler,et al.  Fragonomics: fragment-based drug discovery. , 2005, Current opinion in chemical biology.

[121]  Edgar Jacoby,et al.  Library design for fragment based screening. , 2005, Current topics in medicinal chemistry.

[122]  Yoshihisa Suzuki,et al.  Crystal structures of proto-oncogene kinase Pim1: a target of aberrant somatic hypermutations in diffuse large cell lymphoma. , 2005, Journal of molecular biology.

[123]  J. T. Metz,et al.  Ligand efficiency indices as guideposts for drug discovery. , 2005, Drug discovery today.

[124]  Jun Li,et al.  Structural Basis of Constitutive Activity and a Unique Nucleotide Binding Mode of Human Pim-1 Kinase* , 2005, Journal of Biological Chemistry.

[125]  Stephan C. Schürer,et al.  Prospective Exploration of Synthetically Feasible, Medicinally Relevant Chemical Space , 2005, J. Chem. Inf. Model..

[126]  Riccardo Leardi,et al.  Nature-Inspired Methods in Chemometrics: Genetic Algorithms and Artificial Neural Networks , 2005 .

[127]  Kam Y. J. Zhang,et al.  A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design , 2005, Nature Biotechnology.

[128]  Christopher W Murray,et al.  Fragment-based lead discovery using X-ray crystallography. , 2005, Journal of medicinal chemistry.

[129]  Matthew Clark,et al.  Generalized Fragment-Substructure Based Property Prediction Method , 2005, J. Chem. Inf. Model..

[130]  Robert J. Jilek,et al.  "Lead hopping". Validation of topomer similarity as a superior predictor of similar biological activities. , 2004, Journal of medicinal chemistry.

[131]  Brian Dymock,et al.  Design and Characterization of Libraries of Molecular Fragments for Use in NMR Screening against Protein Targets , 2004, J. Chem. Inf. Model..

[132]  Deepa V. Pednekar,et al.  STUDIES ON NOVEL NON-IMIDAZOLE HUMAN H4 RECEPTOR ANTAGONISTS USING GFA AND FREE-WILSON ANALYSIS , 2004, Medicinal Chemistry Research.

[133]  Robert J. Jilek,et al.  Topomers: A Validated Protocol for Their Self-Consistent Generation , 2004, J. Chem. Inf. Model..

[134]  T. O'Brien,et al.  Fragment-based drug discovery. , 2004, Journal of medicinal chemistry.

[135]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.

[136]  D. Fattori,et al.  Molecular recognition: the fragment approach in lead generation. , 2004, Drug discovery today.

[137]  Chris L. Waller,et al.  A Comparative QSAR Study Using CoMFA, HQSAR, and FRED/SKEYS Paradigms for Estrogen Receptor Binding Affinities of Structurally Diverse Compounds , 2004, J. Chem. Inf. Model..

[138]  M. Congreve,et al.  A 'rule of three' for fragment-based lead discovery? , 2003, Drug discovery today.

[139]  S. Teague Implications of protein flexibility for drug discovery , 2003, Nature Reviews Drug Discovery.

[140]  A. Gołębiowski,et al.  Lead compounds discovered from libraries: part 2. , 2003, Current opinion in chemical biology.

[141]  Robert P. Sheridan,et al.  Finding Multiactivity Substructures by Mining Databases of Drug-Like Compounds , 2003, J. Chem. Inf. Comput. Sci..

[142]  Peter Willett,et al.  Scaffold Searching: Automated Identification of Similar Ring Systems for the Design of Combinatorial Libraries , 2002 .

[143]  Marcel L. Verdonk,et al.  The consequences of translational and rotational entropy lost by small molecules on binding to proteins , 2002, J. Comput. Aided Mol. Des..

[144]  James B. Hendrickson,et al.  Generating Benign Alternative Syntheses: The SynGen Program , 2002 .

[145]  Andrzej M. Brzozowski,et al.  Interaction of Transcriptional Intermediary Factor 2 Nuclear Receptor Box Peptides with the Coactivator Binding Site of Estrogen Receptor α* , 2002, The Journal of Biological Chemistry.

[146]  D. Bentrem,et al.  Structure-Function Relationships of the Raloxifene-Estrogen Receptor-α Complex for Regulating Transforming Growth Factor-α Expression in Breast Cancer Cells* , 2002, The Journal of Biological Chemistry.

[147]  C. F. Shen,et al.  Testing non-additivity of biological activity in a combinatorial library. , 2002, Combinatorial chemistry & high throughput screening.

[148]  Robert P. Sheridan,et al.  The Most Common Chemical Replacements in Drug-Like Compounds , 2002, J. Chem. Inf. Comput. Sci..

[149]  Matthias Rarey,et al.  Similarity searching in large combinatorial chemistry spaces , 2001, J. Comput. Aided Mol. Des..

[150]  A Golebiowski,et al.  Lead compounds discovered from libraries. , 2001, Current opinion in chemical biology.

[151]  Andrew R. Leach,et al.  Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery , 2001, J. Chem. Inf. Comput. Sci..

[152]  A. Bitonti,et al.  Crystal structure of human cyclin-dependent kinase 2 in complex with the adenine-derived inhibitor H717. , 2001, Journal of medicinal chemistry.

[153]  Jean M. Severin,et al.  Design of adenosine kinase inhibitors from the NMR-based screening of fragments. , 2000, Journal of medicinal chemistry.

[154]  A. Petrauskas,et al.  ACD/Log P method description , 2000 .

[155]  Jun Xu,et al.  Drug-like Index: A New Approach To Measure Drug-like Compounds and Their Diversity , 2000, J. Chem. Inf. Comput. Sci..

[156]  A H Calvert,et al.  Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. , 2000, Journal of medicinal chemistry.

[157]  G. Albers,et al.  Eyes Wide Open , 2000 .

[158]  D. Kostrewa,et al.  Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening. , 2000, Journal of medicinal chemistry.

[159]  R C Wade,et al.  Nuclear receptor-DNA binding specificity: A COMBINE and Free-Wilson QSAR analysis. , 2000, Journal of medicinal chemistry.

[160]  R. Cramer,et al.  Toward general methods of targeted library design: topomer shape similarity searching with diverse structures as queries. , 2000, Journal of medicinal chemistry.

[161]  G. Bemis,et al.  Properties of known drugs. 2. Side chains. , 1999, Journal of medicinal chemistry.

[162]  Schmid,et al.  "Scaffold-Hopping" by Topological Pharmacophore Search: A Contribution to Virtual Screening. , 1999, Angewandte Chemie.

[163]  Ajay,et al.  The SHAPES strategy: an NMR-based approach for lead generation in drug discovery. , 1999, Chemistry & biology.

[164]  K. Schaper,et al.  FREE-WILSON-TYPE ANALYSIS OF NON-ADDITIVE SUBSTITUENT EFFECTS ON THPB DOPAMINE RECEPTOR AFFINITY USING ARTIFICIAL NEURAL NETWORKS , 1999 .

[165]  R. Cramer,et al.  Prospective identification of biologically active structures by topomer shape similarity searching. , 1999, Journal of medicinal chemistry.

[166]  P. Hajduk,et al.  High-throughput nuclear magnetic resonance-based screening. , 1999, Journal of medicinal chemistry.

[167]  John W. Erickson,et al.  Conformational switching in an aspartic proteinase , 1998, Nature Structural Biology.

[168]  Matthias Rarey,et al.  Feature trees: A new molecular similarity measure based on tree matching , 1998, J. Comput. Aided Mol. Des..

[169]  S H Kim,et al.  Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. , 1998, Science.

[170]  Robert D. Clark,et al.  Virtual Compound Libraries: A New Approach to Decision Making in Molecular Discovery Research , 1998, J. Chem. Inf. Comput. Sci..

[171]  R M Stroud,et al.  The additivity of substrate fragments in enzyme-ligand binding. , 1998, Structure.

[172]  Yu Chen,et al.  Evaluation of Quantitative Structure-Activity Relationship Methods for Large-Scale Prediction of Chemicals Binding to the Estrogen Receptor , 1998, J. Chem. Inf. Comput. Sci..

[173]  Michael M. Hann,et al.  RECAP-Retrosynthetic Combinatorial Analysis Procedure: A Powerful New Technique for Identifying Privileged Molecular Fragments with Useful Applications in Combinatorial Chemistry , 1998, J. Chem. Inf. Comput. Sci..

[174]  Zbigniew Dauter,et al.  Molecular basis of agonism and antagonism in the oestrogen receptor , 1997, Nature.

[175]  L. Meijer,et al.  Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. , 1997, European journal of biochemistry.

[176]  K A Dill,et al.  Additivity Principles in Biochemistry* , 1997, The Journal of Biological Chemistry.

[177]  C A Marchant,et al.  Prediction of rodent carcinogenicity using the DEREK system for 30 chemicals currently being tested by the National Toxicology Program. The DEREK Collaborative Group. , 1996, Environmental health perspectives.

[178]  G. Bemis,et al.  The properties of known drugs. 1. Molecular frameworks. , 1996, Journal of medicinal chemistry.

[179]  Johann Gasteiger,et al.  Computer‐Assisted Planning of Organic Syntheses: The Second Generation of Programs , 1996 .

[180]  L Meijer,et al.  Multiple modes of ligand recognition: Crystal structures of cyclin‐dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine , 1995, Proteins.

[181]  Kornelia Polyak,et al.  Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex , 1995, Nature.

[182]  W F van Gunsteren,et al.  Decomposition of the free energy of a system in terms of specific interactions. Implications for theoretical and experimental studies. , 1994, Journal of molecular biology.

[183]  Shaomeng Wang,et al.  Computer Automated log P Calculations Based on an Extended Group Contribution Approach , 1994, J. Chem. Inf. Comput. Sci..

[184]  Paul A. Bartlett,et al.  CAVEAT: A program to facilitate the design of organic molecules , 1994, J. Comput. Aided Mol. Des..

[185]  A. Leo CALCULATING LOG POCT FROM STRUCTURES , 1993 .

[186]  W. G. Richards,et al.  Application of Neural Networks: Quantitative Structure-Activity Relationships of the Derivatives of 2,4-Diamino-5-(substituted-benzyl) pyrimidines as DHFR Inhibitors. , 1993 .

[187]  S. So,et al.  Application of neural networks: quantitative structure-activity relationships of the derivatives of 2,4-diamino-5-(substituted-benzyl)pyrimidines as DHFR inhibitors. , 1992, Journal of medicinal chemistry.

[188]  T. A. Andrea,et al.  Applications of neural networks in quantitative structure-activity relationships of dihydrofolate reductase inhibitors. , 1991, Journal of medicinal chemistry.

[189]  D. Sanderson,et al.  Computer Prediction of Possible Toxic Action from Chemical Structure; The DEREK System , 1991, Human & experimental toxicology.

[190]  Arup K. Ghose,et al.  Atomic physicochemical parameters for three dimensional structure directed quantitative structure-activity relationships. 4. Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring nucleoside antibiotics , 1989, J. Chem. Inf. Comput. Sci..

[191]  B. E. Evans,et al.  Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. , 1988, Journal of medicinal chemistry.

[192]  R. Cramer,et al.  Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.

[193]  V. E. Golender,et al.  Structure-activity relationship oriented languages for chemical structure representation , 1982, J. Chem. Inf. Comput. Sci..

[194]  W. Jencks,et al.  On the attribution and additivity of binding energies. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[195]  Peter C. Jurs,et al.  Computer-Assisted Computation of Partition Coefficients from Molecular Structures Using Fragment Constants , 1979, J. Chem. Inf. Comput. Sci..

[196]  H. Rappaport Evaluation of group contributions to ligand binding. , 1979, Journal of theoretical biology.

[197]  L. Hodes,et al.  A statistical-heuristic methods for automated selection of drugs for screening. , 1977, Journal of medicinal chemistry.

[198]  Peter C. Jurs,et al.  Generation of Descriptors from Molecular Structures , 1976, J. Chem. Inf. Comput. Sci..

[199]  Peter C. Jurs,et al.  ADAPT: A Computer System for Automated Data Analysis Using Pattern Recognition Techniques , 1976, J. Chem. Inf. Comput. Sci..

[200]  C Silipo,et al.  Calculation of hydrophobic constant (log P) from pi and f constants. , 1975, Journal of medicinal chemistry.

[201]  C E Berkoff,et al.  Substructural analysis. A novel approach to the problem of drug design. , 1974, Journal of medicinal chemistry.

[202]  A B Glaz,et al.  Cybernetic methods of drug design. I. Statement of the problem--the perceptron approach. , 1973, Computers and biomedical research, an international journal.

[203]  T. Fujita,et al.  Structure-activity study of phenethylamines as substrates of biosynthetic enzymes of sympathetic transmitters. , 1971, Journal of medicinal chemistry.

[204]  E J Corey,et al.  Computer-assisted design of complex organic syntheses. , 1969, Science.

[205]  S. Free,et al.  A MATHEMATICAL CONTRIBUTION TO STRUCTURE-ACTIVITY STUDIES. , 1964, Journal of medicinal chemistry.

[206]  Peter Kolb,et al.  Docking screens: right for the right reasons? , 2009, Current topics in medicinal chemistry.

[207]  Sudhir A. Kulkarni,et al.  Group‐Based QSAR (G‐QSAR): Mitigating Interpretation Challenges in QSAR , 2009 .

[208]  I. Hațieganu,et al.  A QSAR Study on Antimicrobial Activity of Some New Sulfonylhydrazinothiazoles , 2008 .

[209]  Stefan Wetzel,et al.  The Scaffold Tree - Visualization of the Scaffold Universe by Hierarchical Scaffold Classification , 2007, J. Chem. Inf. Model..

[210]  Michal Vieth,et al.  Drugs in other drugs: a new look at drugs as fragments. , 2007, Drug discovery today.

[211]  S. G. Kaskhedikar,et al.  Exploring structural feature of aldose-reductase inhibition by 5-[[2-(omega-carboxyalkoxy)aryl]methylene]-4-oxo-2-thioxothiazolidine derivatives employing Fujita-Ban and Hansch approach. , 2007, Chemical & pharmaceutical bulletin.

[212]  L. Strekowski,,et al.  Fujita-Ban QSAR analysis and CoMFA study of quinoline antagonists of immunostimulatory CpG-oligodeoxynucleotides. , 2007, Bioorganic & medicinal chemistry.

[213]  Gilles Marcou,et al.  Optimizing Fragment and Scaffold Docking by Use of Molecular Interaction Fingerprints , 2007, J. Chem. Inf. Model..

[214]  Jürgen Bajorath,et al.  Chemical Database Mining through Entropy-Based Molecular Similarity Assessment of Randomly Generated Structural Fragment Populations , 2007, J. Chem. Inf. Model..

[215]  M. Hack,et al.  Pyrazole CCK(1) receptor antagonists. Part 2: SAR studies by solid-phase library synthesis and determination of Free-Wilson additivity. , 2006, Bioorganic & medicinal chemistry letters.

[216]  I. Pajeva,et al.  QSAR and 3D QSAR of inhibitors of the epidermal growth factor receptor , 2006 .

[217]  Matthew Clark,et al.  Grand Canonical Monte Carlo Simulation of Ligand-Protein Binding , 2006, J. Chem. Inf. Model..

[218]  Matthew Clark,et al.  Development and Evaluation of an in Silico Model for hERG Binding , 2006, J. Chem. Inf. Model..

[219]  M. Hack,et al.  Pyrazole CCK(1) receptor antagonists. Part 1: Solution-phase library synthesis and determination of Free-Wilson additivity. , 2006, Bioorganic & medicinal chemistry letters.

[220]  Peter Kirkpatrick Antiviral drugs: Inside the envelope , 2004, Nature Reviews Drug Discovery.

[221]  Paul Gillespie,et al.  The Hit-to-Lead Process in Drug Discovery , 2004 .

[222]  Marjan Vračko,et al.  Artificial neural networks in molecular structures—property studies , 2003 .

[223]  R. Cramer,et al.  Topomer CoMFA: a design methodology for rapid lead optimization. , 2003, Journal of medicinal chemistry.

[224]  Ola Engkvist,et al.  Prediction of CNS Activity of Compound Libraries Using Substructure Analysis , 2003, J. Chem. Inf. Comput. Sci..

[225]  Knut Baumann,et al.  An Alignment-Independent Versatile Structure Descriptor for QSAR and QSPR Based on the Distribution of Molecular Features , 2002, J. Chem. Inf. Comput. Sci..

[226]  P N Judson,et al.  Knowledge-based expert systems for toxicity and metabolism prediction: DEREK, StAR and METEOR. , 1999, SAR and QSAR in environmental research.

[227]  D Szwajkajzer,et al.  Molecular and biological constraints on ligand-binding affinity and specificity. , 1997, Biopolymers.

[228]  R. Mannhold,et al.  Calculation Procedures for Molecular Lipophilicity: a Comparative Study† , 1996 .

[229]  F. Burden Using Artificial Neural Networks to Predict Biological Activity from Simple Molecular Structural Considerations , 1996 .

[230]  W. Meylan,et al.  Atom/fragment contribution method for estimating octanol-water partition coefficients. , 1995, Journal of pharmaceutical sciences.

[231]  Raimund Mannhold,et al.  Calculation of Drug Lipophilicity: The Hydrophobic Fragmental Constant Approach , 1992 .

[232]  B. Kowalski,et al.  Partial least-squares regression: a tutorial , 1986 .

[233]  P. Andrews,et al.  Functional group contributions to drug-receptor interactions. , 1984, Journal of medicinal chemistry.

[234]  A. Leo,et al.  Substituent constants for correlation analysis in chemistry and biology , 1979 .

[235]  Rf Rekker,et al.  THE HYDROPHOBIC FRAGMENTAL CONSTANT; AN EXTENSION TO A 1000 DATA POINT SET , 1979 .

[236]  A. H. Lipkus,et al.  Structural Diversity of Organic Chemistry. a Scaffold Analysis of the Cas Registry , 2022 .

[237]  Universities of Leeds, Sheffield and York , 2022 .